US WorldMeds acquires Solstice Neurosciences

LOUISVILLE, Ky. US WorldMeds has acquired Solstice Neurosciences for $35.7 million, US WorldMeds said.

The acquisition gives US WorldMeds control of Malvern, Pa.-based Solstice’s Myobloc (rimabotulinumtoxinB), an injectable drug used to treat cervical dystonia. Cervical dystonia is a disorder that causes the head and neck to twist uncontrollably.

“By acquiring Solstice Neurosciences, US WorldMeds is bringing together the knowledge, passion and innovative spirit of two leading-edge companies,” US WorldMeds CEO P. Breckinridge Jones said. “US WorldMeds is dedicated to leveraging our scientific expertise to develop novel specialty pharmaceuticals that make a difference in patients’ lives.”